PharmaSourcesJune 22, 2021
Tag: Cefazolin sodium , cephalosporin , API Powder
Cefazolin sodium is a broad-spectrum beta-lactam antibiotic belonging to the cephalosporin class of antibiotics. It is the salt form of cefazolin and is classified as a first-generation cephalosporin. It is effective against an array of mild, moderate, and severe bacterial infections. Ancef is the brand name.
Cefazolin sodium is the salt form of cefazolin. Each 500 mg vial of powder for injection contains cefazolin sodium equivalent to 500 mg of cefazolin while each 1-gram vial contains cefazolin sodium equivalent to 1 gram of cefazolin.
Cefazolin and cephalexin are both first-generation cephalosporins. Cefazolin’s brand name is Ancef. Cephalexin’s brand name is Keflex. Cefazolin is only available as a powder for injection, whereas cephalexin is available as a tablet, capsule, and oral suspension.
Cefazolin sodium is available in a couple of different forms and specifications including cefazolin sodium API powder and cefazolin sodium injection.
Cefazolin sodium is the salt form of cefazolin. Raw material of cefazolin sodium API powder (CAS
27164-46-1) is in the form of an off-white to white crystalline powder. The specification from Chinese manufacturers Sinopharm Weiqida Pharmaceutical Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., and CSPC PHARMA is 99% min.
Cefazolin powder for injection is supplied in 500 mg vials and 1-gram vials. Each 500 mg vial contains
sterile cefazolin sodium equivalent to 500 mg of cefazolin. Each 1-gram vial contains sterile cefazolin
sodium equivalent to 1 gram of cefazolin. The 500 mg vials contain 24 mg of sodium, and the 1-gram vials contain 48 mg of sodium. Cefazolin is also available in a 10-gram bulk vial.
Cefazolin sodium exterts its bactericidal activity by binding to penicillin-binding proteins on the inside of the bacterial cell wall’s membrane. The penicillin-binding proteins are deactivated, causing the breakdown of the bacterial cell wall and ultimately, death of the bacteria (“PubChem Compound Summary for CID 23675322,Cefazolin sodium”).
The manufacturing process of cefazolin sodium API is completed under proper quality control systems that must comply with the regulations of international Good Manufacturing Practice (GMP) to ensure safe and high-quality active pharmaceutical ingredients.
Cefazolin sodium is the salt form of cefazolin. Chemical reactions are involved, converting “7-aminocephalosporanic acid to its sodium salt and acetylated with 1H-tetrazole-1-acetyl chloride” (“PubChem Compound Summary for CID 33255, Cefazolin"). The acetoxy group is disarranged with 5-methyl-1,3,4-thiadiazole-2-thiol in a buffer solution (“PubChem Compound Summary for CID 33255, Cefazolin"). Cefazolin acid is isolated and converted to the salt form of cefazolin, cefazolin sodium, with sodium bicarbonate (“PubChem Compound Summary for CID 33255, Cefazolin").
Impurities are then extracted from the active ingredient by crystallization, centrifugation, drying, filtration, milling, and/or sieving. Cefazolin sodium is tested and purified in accordance with quality standards until it achieves 99% min purity specification.
Cefazolin sodium is used to treat a variety of mild, moderate, and severe bacterial infections including urinary tract infections (UTIs), pneumococcal pneumonia, endocarditis, and septicemia.
The usual dose of cefazolin sodium for adults is 500 mg to 1 gram intravenously (IV) every 8 hours. For moderate to severe infections, the dose is 500 mg to 1 gram IV every 6 hours - 8 hours. For severe, life-threatening infections, the dose is 1 to 1.5 grams IV every 6 hours. The maximum dose per day is 12 grams.
Side effects of cefazolin sodium include redness or swelling at the injection site, nausea, vomiting, diarrhea, headache.
Below are some manufacturers who are professional in making API active product ingredient.
Chinese manufacturers, Sinopharm Weiqida Pharmaceutical Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., and CSPC PHARMA manufacture raw material of cefazolin sodium API powder 99% in bulk. If you need a price quote and certificate of analysis (COA) or a detailed specification sheet, please visit these professional manufacturers on www.pharmasources.com.
Established in 2002, Sinopharm Weiqida Pharmaceutical Co., Ltd. is located in the historical and cultural “coal capital” city of Datong, China. They specialize in pharmaceutical raw materials, antibiotic intermediates, and finished products. For more information about Sinopharm Weiqida Pharmaceutical Co., Ltd., visit www.pharmasources.com.
Established in 1966, Shandong Lukang Pharmaceutical Co., Ltd. has more than 50 years of pharmaceutical manufacturing experience. They are China’s leading manufacturer of antibiotic products and have been listed in the Shanghai Stock Exchange for more than 20 years. They specialize in the research, development, manufacturing, and sales of active pharmaceutical ingredients (API), intermediates, and finished products for human, vet, and agricultural use.
With an intent focus on providing safe, high-quality products while protecting the health and safety of their employees and the environment, they hold ISO 9001, 14001, and 18001 certifications. They also hold Good Manufacturing Practice certification with regular inspections completed by the State Food and Drug Administration. For more information about Shandong Lukang Pharmaceutical Co., Ltd., visit www.pharmasources.com.
CSPC PHARMA was established in 1997 and is now a national innovator of research, development, manufacturing, and sales of medications. They are the first Chinese pharmaceutical company to be listed in HK stock market. They specialize in APIs, anti-tumor medications, generics, innovative medications, pharmaceutical logistics, massive health, and investments and financing. Their market expands from China to more than 100 countries and regions around the world. For more information about CSPC PHARMA, visit www.pharmasources.com
Pharmasources.com is a professional pharmaceutical platform, committed to providing information about the highest-quality products and suppliers to their global customers. They deliver services to 900,000+ active members across 211 countries and regions, while featuring more than 1,600,000 products in 30 major categories that span the entire pharma supply chain. Their mission is “to connect global buyers with quality suppliers and facilitate easy trade of the pharmaceutical industry” (PharmaSources).
Cefazolin is a first-generation cephalosporin.
Cefazolin treats a variety of mild, moderate, and severe bacteria. Cefazolin treats urinary tract infections (UTIs), pneumococcal pneumonia, endocarditis, and septicemia.
Another name for cefazolin is Ancef.
1. Cefazolin. DrugBank. https://go.drugbank.com/drugs/DB01327. Updated June 5, 2021. Accessed June 5, 2021.
2. Cefazolin. GlobalRPh. https://globalrph.com/renal/cefazolin/. Accessed June 5, 2021.
3. Cefazolin Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682731.html. Last revised June 15, 2016. Accessed June 5, 2021.
4. Cefazolin – Pharmacology Cefazolin Sodium. healthgrades. https://www.healthgrades.com/drugs/cefazolin-cefazolin-sodium-injection-powder-for-solution/pharmacology. Accessed June
5, 2021.
5. Cefazolin sodium salt. Chemical Book. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7403213.htm. Accessed June 5, 2021.
6. Company Profile of CSPC PHARMA. PharmaSources. https://www.pharmasources.com/company-home/cspc-pharma-userId-148.html. Accessed June 5, 2021.
7. Company Profile of Shandong Lukang Pharmaceutical Co., Ltd. PharmaSources. https://www.pharmasources.com/company-profile/shandong-lukang-pharmaceutical-co-ltd-userId-968.html. Accessed June 5, 2021.
8. Company Profile of Sinopharm Weiqida Pharmaceutical Co. PharmaSources.
https://www.pharmasources.com/company-profile/sinopharm-weiqida-pharmaceutical-co-ltd-userId-171.html. Accessed June 5, 2021.
9. Compare cefazolin vs. Keflex: Head-to-head comparisons of medication sues, side effects, ratings, and more. Iodine. https://www.iodine.com/compare/cefazolin-vs-keflex. Accessed June 5, 2021.
10. National Center for Biotechnology Information. "PubChem Compound Summary for CID
23675322,Cefazolin sodium" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Cefazolin-sodium. Accessed 5 June, 2021.
11. National Center for Biotechnology Information. "PubChem Compound Summary for CID 33255, Cefazolin" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Cefazolin. Accessed 5 June, 2021.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: